EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

FHL1: A novel diagnostic marker for papillary thyroid carcinoma

Yeting Zeng, Dehua Zeng, Xingfeng Qi, Hanxi Wang, Xuzhou Wang, Xiaodong Dai, Lijuan Qu

Pathology International · 2024

DOI: 10.1111/pin.13467 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology International, 2024. Verfasst von Yeting Zeng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Joint Logistic Support Force 900th Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Thyroid Neoplasms, Thyroid Cancer, Papillary, LIM Domain Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fujian Province clinical key specialty construction project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although there are clear morphologic criteria for the diagnosis of papillary thyroid carcinoma (PTC), when the morphology is untypical or overlaps, accurate diagnostic indicators are necessary. Since few studies investigated the role of down‐regulated genes in PTC, this article aims to further explore the molecular markers associated with PTC. We conducted bioinformatics analysis of gene microarrays of PTC and normal adjacent tissues. Besides, quantitative real‐time quantitative polymerase chain reaction array and immunohistochemical staining were used to investigate the expression of the major down‐regulated genes. The results indicated that several important down‐regulated genes, including TLE1, BCL2, FHL1, GHR, KIT, and PPARGC1A were involved in the process of PTC. Compared to normal adjacent tissues, the mRNA expression of the major genes was down‐regulated in PTC ( p <0.05). Immunohistochemically, FHL1 shows negative or low expression in PTC tissues ( p <0.05). BCL2 did not show a significant difference between PTC and normal thyroid tissues ( p > 0.05). TLE1, KIT, PPARGC1A and GHR showed negative expression in both tumor and normal tissues. These results suggested that FHL1 could serve as a novel tumor marker for precise diagnosis of PTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorThyroid NeoplasmsThyroid Cancer, PapillaryLIM Domain ProteinsIntracellular Signaling Peptides and ProteinsMuscle ProteinsHumansMaleFemaleMiddle AgedAdultAgedGene Expression Regulation, NeoplasticImmunohistochemistryCarcinoma, Papillary

Stichwörter der Autor:innen

FHL1PTCbioinformatics analysisbiomarkerdown‐regulated DEGs

Substanzen

Biomarkers, TumorLIM Domain ProteinsFHL1 protein, humanIntracellular Signaling Peptides and ProteinsMuscle Proteins

Autor:innen und Institutionen

  • Department of Pathology, Joint Logistic Support Force 900th Hospital, Fuzhou, China.
  • Department of clinical pathology, Medical Research Center, Fujian Medical University, Fuzhou, China.

Förderung

  • Fujian Province clinical key specialty construction project

Zitieren

APA

Zeng, Y., Zeng, D., Qi, X., Wang, H., Wang, X., Dai, X., & Qu, L. (2024). FHL1: A novel diagnostic marker for papillary thyroid carcinoma. Pathology International. https://doi.org/10.1111/pin.13467

Vancouver

Zeng Y, Zeng D, Qi X, Wang H, Wang X, Dai X, et al. FHL1: A novel diagnostic marker for papillary thyroid carcinoma. Pathology International. 2024. doi:10.1111/pin.13467

BibTeX
@article{Zeng2024,
  author = {Zeng, Yeting and Zeng, Dehua and Qi, Xingfeng and Wang, Hanxi and Wang, Xuzhou and Dai, Xiaodong and Qu, Lijuan},
  title = {FHL1: A novel diagnostic marker for papillary thyroid carcinoma},
  journal = {Pathology International},
  year = {2024},
  doi = {10.1111/pin.13467}
}
Kostenlos starten →